Harrow, Inc. is an ophthalmology-focused pharmaceutical company that discovers, develops, and commercializes eye care medications. The company operates through a portfolio of branded ophthalmic products and compounded pharmaceutical services, serving the specialty pharmaceutical segment of the healthcare industry.
The company's product portfolio spans multiple therapeutic areas within ophthalmology, including anti-inflammatory agents (ILEVRO, NEVANAC), antibiotic eye drops (VIGAMOX), corticosteroid formulations (MAXIDEX, FLAREX, TRIESENCE), and anti-allergy medications (ZERVIATE). ImprimisRx, the company's ophthalmology-focused compounded medication service, represents a significant business segment. Additional offerings include IHEEZO (a topical anesthetic gel), IOPIDINE, lubricant eye drops (FRESHKOTE), and VERKAZIA for dry eye disease treatment, among others.
Based in Nashville, Tennessee, Harrow operates with approximately 382 full-time employees. The company is incorporated in Delaware and trades on Nasdaq. Harrow was founded in 1998 and underwent a corporate name change from Harrow Health, Inc. in September 2023. Its product distribution and commercialization activities extend across the United States ophthalmology market, targeting eye care specialists, surgical centers, and hospital systems.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.49 | $-0.49 | +34.7% | |
| 2023 | $-0.75 | $-0.75 | -47.1% | |
| 2022 | — | $-0.51 | — | |
| 2021 | — | — | — | |
| 2020 | $-0.13 | $-0.13 | -1400.0% | |
| 2019 | $0.01 | $0.01 | -98.4% | |
| 2018 | $0.61 | $0.67 | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-27 | 0001641172-25-000925 | SEC ↗ |
| 2023-12-31 | 2024-03-19 | 0001493152-24-010518 | SEC ↗ |
| 2022-12-31 | 2023-03-23 | 0001493152-23-008718 | SEC ↗ |
| 2021-12-31 | 2022-03-10 | 0001493152-22-006525 | SEC ↗ |
| 2020-12-31 | 2021-03-08 | 0001493152-21-005583 | SEC ↗ |
| 2019-12-31 | 2020-03-13 | 0001493152-20-003862 | SEC ↗ |
| 2018-12-31 | 2019-03-12 | 0001493152-19-003188 | SEC ↗ |
| 2017-12-31 | 2018-03-08 | 0001493152-18-003095 | SEC ↗ |
| 2016-12-31 | 2017-03-21 | 0001493152-17-002687 | SEC ↗ |
| 2015-12-31 | 2016-03-23 | 0001493152-16-008212 | SEC ↗ |
| 2014-12-31 | 2015-03-12 | 0001493152-15-000811 | SEC ↗ |
| 2013-12-31 | 2014-03-28 | 0001493152-14-000878 | SEC ↗ |
| 2012-12-31 | 2013-03-18 | 0001354488-13-001295 | SEC ↗ |
| 2011-12-31 | 2012-02-23 | 0001354488-12-000844 | SEC ↗ |
| 2010-12-31 | 2012-02-23 | 0001354488-12-000836 | SEC ↗ |
| 2009-12-31 | 2010-03-31 | 0000950123-10-030880 | SEC ↗ |
| 2008-12-31 | 2009-03-26 | 0000936392-09-000134 | SEC ↗ |